BIO Comments on "Considerations in Demonstrating Interchangeability with a Reference Product"
December 5, 2017
The Biotechnology Innovation Organization ("BIO") welcomes the opportunity to submit comments on the Food and Drug Administration (FDA) draft guidance titled "Considerations in Demonstrating Interchangeability With a Reference Product" issued on January 18, 2017 ("Draft Guidance").
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, and environmental biotechnology products, thereby expanding the boundaries of science to benefit humanity by providing better healthcare, enhanced agriculture, and a cleaner and safer environment.
Implementation of the Biologics Price Competition and Innovation Act ("BPCIA") remains of significant importance to BIO members. Thus, we greatly appreciate FDA's issuance of the long-awaited draft guidance on demonstrating interchangeability pursuant to section 351 (k)( 4) of the Public Health Service Act (PHSA) (42 U.S.C. 262(k)(4)).
Download Full Comments Below
BIO Comments On Docket No. FDA-2017-D-0154 Draft Guidance On Considerati...
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
The Biotechnology Innovation Organization ("BIO") welcomes the opportunity to submit comments on the Food and Drug Administration (FDA) draft guidance titled "Considerations in Demonstrating Interchangeability With a Reference Product" issued on January 18, 2017 ("Draft Guidance").
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, and environmental biotechnology products, thereby expanding the boundaries of science to benefit humanity by providing better healthcare, enhanced agriculture, and a cleaner and safer environment.
Implementation of the Biologics Price Competition and Innovation Act ("BPCIA") remains of significant importance to BIO members. Thus, we greatly appreciate FDA's issuance of the long-awaited draft guidance on demonstrating interchangeability pursuant to section 351 (k)( 4) of the Public Health Service Act (PHSA) (42 U.S.C. 262(k)(4)).